Impact of Posterior Vitreous Detachment on Treatment Outcomes in Diabetic Macular Edema

Ophthalmol Retina. 2020 Apr;4(4):452-454. doi: 10.1016/j.oret.2019.12.002. Epub 2019 Dec 9.

Authors

Ferhina Ali¹, Sundeep Kasi², Namrata Saroj³, Keith Baker³, Desmond Thompson³, Robert Vitti³, Alyson J Berliner³, Carola Metzig⁴, Allen C Ho⁵

Affiliations

¹ Retina Center of Texas, Dallas, Texas.
² Retina Group of Washington, Alexandria, Virginia.
³ Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
⁴ Bayer Healthcare, Berlin, Germany.
⁵ Wills Eye Hospital, Philadelphia, Pennsylvania; Thomas Jefferson University, Philadelphia, Pennsylvania; Mid Atlantic Retina, Philadelphia, Pennsylvania. Electronic address: acho@midatlanticretina.com.

PMID: 31982388
DOI: 10.1016/j.oret.2019.12.002

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Angiogenesis Inhibitors / administration & dosage
Diabetic Retinopathy / complications
Diabetic Retinopathy / diagnosis
Diabetic Retinopathy / drug therapy*
Fluorescein Angiography
Fundus Oculi
Humans
Intravitreal Injections
Macular Edema / diagnosis
Macular Edema / drug therapy*
Macular Edema / etiology
Receptors, Vascular Endothelial Growth Factor / administration & dosage*
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
Recombinant Fusion Proteins / administration & dosage*
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity*
Vitreous Detachment / diagnosis
Vitreous Detachment / etiology*

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
aflibercept
Receptors, Vascular Endothelial Growth Factor